The Cost-Effectiveness of Surgical Intervention for Spinal Metastases: A Model-Based Evaluation.


Journal

The Journal of bone and joint surgery. American volume
ISSN: 1535-1386
Titre abrégé: J Bone Joint Surg Am
Pays: United States
ID NLM: 0014030

Informations de publication

Date de publication:
21 Jul 2021
Historique:
entrez: 21 7 2021
pubmed: 22 7 2021
medline: 22 7 2021
Statut: aheadofprint

Résumé

Operative and nonoperative treatments for spinal metastases are expensive interventions with a high rate of complications. We sought to determine the cost-effectiveness of a surgical procedure compared with nonoperative management as treatment for spinal metastases. We constructed a Markov state-transition model with health states defined by ambulatory status and estimated the quality-adjusted life-years (QALYs) and costs for operative and nonoperative management of spine metastases. We considered 2 populations: 1 in which patients presented with independent ambulatory status and 1 in which patients presented with nonambulatory status due to acute (e.g., <48 hours) metastatic epidural compression. We defined the efficacy of each treatment as a likelihood of maintaining, or returning to, independent ambulation. Transition probabilities for the model, including the risks of mortality and becoming dependent or nonambulatory, were obtained from secondary data analysis and published literature. Costs were determined from Medicare reimbursement schedules. We conducted analyses over patients' remaining life expectancy from a health system perspective and discounted outcomes at 3% per year. We conducted sensitivity analyses to account for uncertainty in data inputs. Among patients presenting as independently ambulatory, QALYs were 0.823 for operative treatment and 0.800 for nonoperative treatment. The incremental cost-effectiveness ratio (ICER) for a surgical procedure was $899,700 per QALY. Among patients presenting with nonambulatory status, those undergoing surgical intervention accumulated 0.813 lifetime QALY, and those treated nonoperatively accumulated 0.089 lifetime QALY. The incremental cost-effectiveness ratio for a surgical procedure was $48,600 per QALY. The cost-effectiveness of a surgical procedure was most sensitive to the variability of its efficacy. Our data suggest that the value to society of a surgical procedure for spinal metastases varies according to the features of the patient population. In patients presenting as nonambulatory due to acute neurologic compromise, surgical intervention provides good value (ICER, $48,600 per QALY). There is a low value for a surgical procedure performed for patients who are ambulatory at presentation (ICER, $899,700 per QALY). Economic and Decision Analysis Level III. See Instructions for Authors for a complete description of levels of evidence.

Sections du résumé

BACKGROUND BACKGROUND
Operative and nonoperative treatments for spinal metastases are expensive interventions with a high rate of complications. We sought to determine the cost-effectiveness of a surgical procedure compared with nonoperative management as treatment for spinal metastases.
METHODS METHODS
We constructed a Markov state-transition model with health states defined by ambulatory status and estimated the quality-adjusted life-years (QALYs) and costs for operative and nonoperative management of spine metastases. We considered 2 populations: 1 in which patients presented with independent ambulatory status and 1 in which patients presented with nonambulatory status due to acute (e.g., <48 hours) metastatic epidural compression. We defined the efficacy of each treatment as a likelihood of maintaining, or returning to, independent ambulation. Transition probabilities for the model, including the risks of mortality and becoming dependent or nonambulatory, were obtained from secondary data analysis and published literature. Costs were determined from Medicare reimbursement schedules. We conducted analyses over patients' remaining life expectancy from a health system perspective and discounted outcomes at 3% per year. We conducted sensitivity analyses to account for uncertainty in data inputs.
RESULTS RESULTS
Among patients presenting as independently ambulatory, QALYs were 0.823 for operative treatment and 0.800 for nonoperative treatment. The incremental cost-effectiveness ratio (ICER) for a surgical procedure was $899,700 per QALY. Among patients presenting with nonambulatory status, those undergoing surgical intervention accumulated 0.813 lifetime QALY, and those treated nonoperatively accumulated 0.089 lifetime QALY. The incremental cost-effectiveness ratio for a surgical procedure was $48,600 per QALY. The cost-effectiveness of a surgical procedure was most sensitive to the variability of its efficacy.
CONCLUSIONS CONCLUSIONS
Our data suggest that the value to society of a surgical procedure for spinal metastases varies according to the features of the patient population. In patients presenting as nonambulatory due to acute neurologic compromise, surgical intervention provides good value (ICER, $48,600 per QALY). There is a low value for a surgical procedure performed for patients who are ambulatory at presentation (ICER, $899,700 per QALY).
LEVEL OF EVIDENCE METHODS
Economic and Decision Analysis Level III. See Instructions for Authors for a complete description of levels of evidence.

Identifiants

pubmed: 34288901
doi: 10.2106/JBJS.21.00023
pii: 00004623-990000000-00293
pmc: PMC8776911
mid: NIHMS1725182
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAMS NIH HHS
ID : K23 AR071464
Pays : United States
Organisme : NIAMS NIH HHS
ID : K24 AR057827
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072577
Pays : United States

Informations de copyright

Copyright © 2021 by The Journal of Bone and Joint Surgery, Incorporated.

Déclaration de conflit d'intérêts

Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJS/G617).

Références

Int Orthop. 2017 Jun;41(6):1265-1271
pubmed: 28396928
J Bone Joint Surg Am. 2017 Jul 5;99(13):e71
pubmed: 28678132
Spine J. 2018 Oct;18(10):1956-1958
pubmed: 30055261
Spine J. 2018 Jun;18(6):935-940
pubmed: 29031992
JAMA. 1996 Oct 23-30;276(16):1339-41
pubmed: 8861994
Spine J. 2019 Jan;19(1):144-156
pubmed: 29864546
Neurosurgery. 2019 Oct 1;85(4):E671-E681
pubmed: 30869143
J Am Acad Orthop Surg. 2011 Jan;19(1):37-48
pubmed: 21205766
J Bone Joint Surg Am. 2016 Mar 2;98(5):396-402
pubmed: 26935462
Spine J. 2020 Apr;20(4):572-579
pubmed: 31712164
Spine J. 2015 Nov 1;15(11):2345-50
pubmed: 26160329
PLoS One. 2017 Dec 29;12(12):e0190342
pubmed: 29287117
BMC Cancer. 2015 May 05;15:354
pubmed: 25939658
Spine J. 2016 Apr;16(4):482-90
pubmed: 26409416
Spine J. 2021 Jan;21(1):28-36
pubmed: 32087387
Radiat Oncol. 2012 Oct 12;7:168
pubmed: 23062178
World Neurosurg. 2019 May;125:e537-e543
pubmed: 30716490
Br J Neurosurg. 2016 Jun;30(3):337-44
pubmed: 26901574
Cancer. 2019 Aug 1;125(15):2631-2637
pubmed: 30985913
J Bone Joint Surg Am. 2016 Nov 2;98(21):1767-1776
pubmed: 27807108
World Neurosurg. 2018 Jan;109:e389-e397
pubmed: 28987846
Arch Orthop Trauma Surg. 2012 Jun;132(6):765-71
pubmed: 22327407

Auteurs

Andrew J Schoenfeld (AJ)

Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Gordon P Bensen (GP)

Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts.

Justin A Blucher (JA)

Rutgers Institute for Translational Medicine and Science, Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey.

Marco L Ferrone (ML)

Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Tracy A Balboni (TA)

Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Joseph H Schwab (JH)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Mitchel B Harris (MB)

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Jeffrey N Katz (JN)

Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Elena Losina (E)

Department of Orthopaedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Classifications MeSH